Evidence map›Paper›PMID 39957702›Full record

ReviewCurrent molecular medicine2026

Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.

Mahrokh Abouali Gale Dari, Farhoodeh Ghaedrahmati, Arash Moalemnia, Mitra Ansari Dezfouli, Feryal Savari, Amir Mohammad Zamani, Behnam Ahmadi, Mohammad Nazarbeigi, Maryam Farzaneh, Mojtaba Zehtabi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mahrokh Abouali Gale DariDepartment of Obstetrics and Gynecology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Farhoodeh GhaedrahmatiDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Arash MoalemniaFaculty of Medicine, Dezful University of Medical Sciences, Jundi-Shapur University of Technolog, Dezful, Iran.
Mitra Ansari DezfouliDepartment of Neurology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Feryal SavariDepartment of Medical Basic Sciences, Shoushtar Faculty of Medical Sciences, Islamic Azad University, Shoushtar Branch, Shoushtar, Iran.
Amir Mohammad ZamaniStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Behnam AhmadiStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad NazarbeigiStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Maryam FarzanehFertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mojtaba ZehtabiHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a heterogeneous disease and highly prevalent malignancy affecting women globally. Breast cancer treatments have been demonstrated to elicit significant and long-lasting effects on various aspects of a patient's life, including physical, emotional, social, and financial, highlighting the need for comprehensive cancer care. Recent research suggests that the composition and activity of the gut microbiota may play a crucial role in anticancer responses. Various compositional features of the gut microbial population have been found to influence both the clinical and biological aspects of breast cancer. Notably, the dominance of specific microbial populations in the human intestine may significantly impact the effectiveness of cancer treatment strategies. Therefore, the manipulation of the microbiota to improve the anticancer effects of conventional tumor treatments represents a promising strategy for enhancing the efficacy of cancer therapy. Emerging evidence indicates that alterations in the gut microbiota composition and activity have the potential to impact breast cancer risk and treatment outcomes. In this paper, we conduct a comprehensive investigation of various databases and published articles to explore the impact of gut microbial composition on both the molecular and clinical aspects of breast cancer. We also discuss the implications of our findings for future research directions and clinical strategies.

Indexed as

Breast NeoplasmsGastrointestinal MicrobiomeAnimalsFemaleHumansBreast cancercancer therapychemotherapy/radiation regimensgut floragut microbiotamicroorganism

Identifiers

PMID39957702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.